From TokenPost · · 40s
Parabilis Presents Zolucatetide Data at ESMO
Parabilis Medicines to share Phase 1/2 zolucatetide results for desmoid tumor trial at Oct 24 ESMO Congress.
In brief
Parabilis Medicines to share Phase 1/2 zolucatetide results for desmoid tumor trial at Oct 24 ESMO Congress. Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the European Society for Medical Oncology Congress on Oct 24 to inform Phase 3 desmoid tumor dosing. Originally reported by TokenPost.
Parabilis Medicines
Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the European Society for Medical Oncology Congress on Oct 24.
Dose Optimization Findings
Dose-optimization findings aim to select dosing for a planned Phase 3 desmoid tumor trial based on June 22 data cutoff.
Presentation Details
Presentation occurs 8:45 to 10:15 a.m. ET (12:45 to 14:15 UTC) in Madrid with investor webcast at noon ET.
What it means
Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the European Society for Medical Oncology Congress on Oct 24 to inform Phase 3 desmoid tumor dosing.
